Loss of BRCA1 promotor hypermethylation in recurrent high grade ovarian cancer
S Prieske, K Prieske, SA Joosse, F Trillsch, D Grimm, E Burandt, S Mahner, B Schmalfeldt, K Milde-Langosch, L Oliveira-Ferrer, L Woelber · Geburtshilfe und Frauenheilkunde · 2016 · Heft 10
Bibliografische Angaben
Zusammenfassung
Background/Aim: Approximately 20 – 25% of ovarian cancers are attributable to germline or somatic BRCA1/2 mutations, resulting in defects in the homologous recombination (HR) pathway. Inactivation of these genes can also be mediated by epigenetic changes e.g. hypermethylation of CpG islands in the promoter regions. Aim of this analysis was to evaluate the stability of BRCA1 promoter hypermethylation in recurrent disease after platinum based chemotherapy. Methods: 76 patients with primary and 48 patients with platinum-sensitive recurrent high-grade ovarian cancer were included. Following primary surgery all patie…
